Bristol Myers touts upbeat data for its blockbuster heart drug candidate
While the FDA stretches out its review for Bristol Myers Squibb’s mavacamten, the pharma giant isn’t wasting any time bolstering enthusiasm for the heart drug.
Over the weekend Bristol Myers presented two major sets of data at the American College of Cardiology’s annual conference for mavacamten — which it picked up in the $13 billion MyoKardia acquisition. The take-home message: Not only is the cardiac myosin inhibitor working well in trials, but it should also prove to be “clinically meaningful.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free.